Effect of Tirzepatide on Markers of MASLD in Patients With Obesity — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity — Stella

View on ClinicalTrials.gov

Recruiting

Back to MASLD trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

University of New Mexico Health Sciences Center, Albuquerque, New Mexico

Key details

Phase

Very early testing

Sponsor

University of New Mexico

Collaborators

American Cancer Society, Inc., University of New Mexico Cancer Center

Enrollment target

~8 participants

Started

June 2025

Primary completion

August 2026

Age range

18 Years – 75 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.